The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.
A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.
As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
The New York Times editorial board weighs in on scientific research misconduct.